Valeant Pharmaceuticals International (VRX) Receives ‘Analyst’ Rating

Valeant Pharmaceuticals International (VRX) : 14 analysts are covering Valeant Pharmaceuticals International (VRX) and their average rating on the stock is 2.61, which is read as a Hold. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Valeant Pharmaceuticals International (VRX) also receives 1 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 2 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 7 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Valeant Pharmaceuticals International (VRX) : The highest level Valeant Pharmaceuticals International (VRX) is projected to reach is $81 for the short term and the lowest estimate is at $22. The consolidated price target from 11 rating analysts who initiate coverage on the stock is $42 and the possibility the share price can swing is $15.8.


Also, Brokerage firm Morgan Stanley upgrades its rating on Valeant Pharmaceuticals International (NYSE:VRX). As per the latest information, the brokerage house raises the price target to $42 per share from a prior target of $33. The shares have been rated Overweight. Previously, the analysts had a Equal-weight rating on the shares. The rating by the firm was issued on August 17, 2016.

Valeant Pharmaceuticals International (NYSE:VRX): The stock opened in the green at $27.47 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $27.69 and a low of $27.18 for the day. The stock did not find buyers even at the lows and closed at $27.37 recording a loss of -0.04%. 11,867,252 shares exchanged hands during the trading day. The stock had closed at $27.38 in the previous days trading.

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.